En bloc total biliary resection hepatectomy for the treatment of gallbladder adenosquamous carcinoma: a case report

INTRODUCTION

Gallbladder cancer is a type of biliary tract malignancy with poorly defined pathogenesis, being 2-6 times more prevalent in the female sex in the age group above the fifties.1 This rare type of cancer presents a large variability of incidence over the world, for example, in Chile the incidence is 17.8/100,000 inhabitants, while in the US the incidence is 1.43/100,000 inhabitants, and this data indicates that population external and genetic factors are important to the incidence of this cancer.1-4

Gallbladder adenocarcinoma is the most common histological variant with 90%-95% of incidence. Gallbladder squamous, epidermoid or adenosquamous carcinoma and leiomyosarcoma are considered more unusual, being more found in the literature as case reports.5 6 The lack of symptomatology in this type of lesion precludes early diagnosis even though new radiology methods can favor examination findings.7 8

The prognosis of gallbladder squamous and adenosquamous carcinoma are related to the invasion of adjacent structures and to the technical difficulty of resectability in advanced cases. The effective treatment for patients starting with T1b staging is surgical resection given its low responsiveness to chemotherapy.9 10

Therefore, the aim of this work is to report a case of gallbladder adenosquamous carcinoma treated with en bloc total biliary resection hepatectomy. This case report was submitted and approved by our local ethics committee.

CASE REPORT

A 84-year-old male patient was admitted at the oncology services of Regional Cancer Hospital of Presidente Prudente due to pain in the right hypochondrium with three months of progressive worsening associated with nausea, loss of appetite and weight loss of approximately 8kg in the last months.

Ultrasound routine examination showed the presence of a large mass in the gallbladder adjacent topography that also showed signs of invasion in the liver tissue associated with extrinsic compression of the extra hepatic bile duct.

On physical examination, he presented slightly emaciated, anicteric, with a palpable mass 2cm from the right costal margin. Laboratory tests showed no increase in the bilirubin levels with a total level of 0.9mg/dl and CA19-9 level <37U/ml. He was then classified as ECOG2 and submitted to preoperative staging with chest and abdomen MRI (Figure 1) with intravenous contrast that showed a perivascular mass invasion to the IVB and V hepatic segments and compression of the hepatic hilum. No lymphadenomegaly and distant metastatic disease was evidenced.

Figure 1 Presence of a mass in the gallbladder funicular region topography (narrows) measuring 3.5cm in the largest axis with diffusion restriction associated to gallbladder distension due to a probable lymph node compression in the hepatic hilum. There is no suggestion of liver metastasis or inter-cavo-aortic lymphadenomegaly.

The case was then discussed by the digestive oncological surgery department and the patient underwent surgery confirming the mass in the gallbladder and the compromised liver tissue (Figure 2). A resection of the IVB, V and VI hepatic segments associated to complete resection en bloc of the extrahepatic bile duct since it presented signs of tumor infiltration. Perihilar chains, celiac trunk, peripancreatic and inter-cavo-aortic lymphadenectomy was also performed. Subsequently to the surgical resection, main bile duct reconstruction with Y-Roux jejunostomy was also performed, requiring an anastomosis to the right hepatic duct and one to the left hepatic duct separately. The procedure was carried out with 250ml of blood loss, approximately, without the need of blood transfusion or use of vasoactive drugs. The total surgical time was of 5 hours.

Figure 2 Gallbladder and liver mass on intraoperative findings.

The anatomopathological report confirmed a rare gallbladder adenosquamous carcinoma with T3N0M1 staging with R0 final resection, slightly differentiated with presence of perineural, angiolymphatic, serous and hepatic segment infiltration (Figures 3, 4 and 5) as well as metastasis in 1 of 2 periportal lymph nodes.

Figure 3 AAA100x magnification, hematoxylin-eosin stain histology: neoplasm showing infiltrates that form epidermoid cell blocks with keratinization foci and intense stromal desmoplastic reaction.

Figure 4 AAA400x magnification, hematoxylin-eosin stain histology: neoplasm block with glanduliform arrangement next to the epidermoid neoplasm focus.

Figure 5 Ck5/6 immunohistochemistry: intense membrane and histoplasmic marking on the epidermoid component, negativity on the glandular component.

The patient was discharged on 8th postoperative day with no sign of biliary fistulas. He received neoadjuvant treatment with eight cycles of capecitabine and progressed well.

DISCUSSION

Squamous and adenosquamous carcinomas are rare malignancies that represent about 3% of all gallbladder neoplasms and their silent nature difficult early diagnosis. Some factors can predispose to these types of cancers such as chronic inflammation of the gallbladder, female sex, porcelain gallbladder, gallbladder adenomatous polyposis, mutation in some genes such as TP53, HER-2 and CDKN2A or CDKN2B, infection by Salmonella typhi, and anatomical variants at the choledochal duct junction to the pancreatic duct, pancreas division.11 12

Patients with gallbladder squamous cell carcinoma present themselves to the specialists with large, bulky tumors, often invading adjacent organs and noble structures such as hepatic hilum vessels, which characterize the case as inoperable.13 It has been noticed that these tumors proliferate at a higher rate than those of glandular component. However, these tumors present less lymph node metastases than the autological type. Therefore, it has been concluded that his aggressive behavior is due to the rapid invasion of adjacent organs such as liver, duodenum, transverse colon and stomach, and not to angiolymphatic dissemination.1

Radiographic findings such as intraluminal tumor mass, diffuse thickening of the gallbladder wall, intrahepatic bile duct dilation, and irregular adjacent lesions juxtaposed to the gallbladder fossa may suggest a gallbladder tumor. About laboratory findings, a study with 411 patients showed that there was not statistical significative difference between the group of patients that present abnormal or elevated levels of CA19-9 and the presence of gallbladder squamous or adenosquamous carcinoma.

Therefore, CA19-19 should not be used as a marker for these tumors' diagnosis, even though a large number of patients showed levels above 37 U/ml of this marker.14

As for the cancer pathology, a certain variation in its microscopy can be found. In a study with 121 patients with gallbladder squamous cell carcinoma 34.4% of them had highly differentiated cancer cells. In addition, 61% of the analyzed samples presented keratinization in the cancerous area with typical keratinocytes of varying sizes, as well as eosinophilic cytoplasm.15

Surgical resection is still the more effective and definitive treatment for the cure of this pathology, associated with greater patient survival.16 In the diagnostic suspicion, after clinical and imaging evaluation, the lesion must be resected with free margins and, if necessary, the removal of adjacent organs and lymph nodes must be performed to achieve a R0 resection. From staging T2, extended cholecystectomy, including lymph node dissection and hepatic resection is recommended.17-19 This approach increases the chance of cure and survival for the patient, since this histological variant of gallbladder cancer presents great limitation of systemic chemotherapy.

Although curative treatment for gallbladder cancer can only be achieved with surgical resection, a study showed that individuals with advanced or metastatic tumors can have longer overall survival with gemcitabine in combination with cisplatin for adjuvant treatments.20 However, established adjuvant treatments for gallbladder carcinoma are lacking and more studies must be performed to show how adjuvant treatments affects survival for this type of cancer.21

In conclusion, we report a case of a rare gallbladder adenosquamous carcinoma that was managed with en bloc total biliary resection hepatectomy. The case report and the data in the literature indicate that this type of cancer is a rare condition associated with poor prognosis, difficulties for surgical resection and systemic chemotherapy treatment.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Authors

About the Journal

Journal: Brazilian Journal of Oncology

DOI: 10.1055/s-00059887

e-issn: 2526-8732

Publisher: Thieme Revinter Publicações Ltda.

Publisher address: Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

No citations found for this article.

References

1. Roa, JC and Tapia, O and Cakir, A and Basturk, O and Dursun, N and Akdemir, D. Squamous cell and adenosquamous carcinoma of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol [online]. 2011, vol. 24, p. 1069-1078.

2. Randi, G and Franceschi, S and La Vecchia, C. Gallbladder cancer worldwide: geographic distribution and risk factors. Int J Cancer [online]. 2006, vol. 118, p. 1591-1602.

3. Henson, DE and Schwartz, AM and Nsouli, H and Albores-Saadreva, J. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study. Arch Pathol Lab Med [online]. 2009, vol. 133, p. 67-71.

4. Medina, E and Kaempffer, AM. Cancer mortality in Chile: epidemiological considerations. Rev Med Chil [online]. 2001, vol. 129, p. 1195-1202.

5. Adsay, NV and Klimstra, DS. Benign and malignant tumors of the gallbladder and extrahepatic biliary tract,Surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia, 2009.

6. Albores-Saavedra, J and Henson, DE and Klimstra, DS. Gallbladder cancer. Armed Forces Institute of Pathology (AFIP), 2000.

7. Kanthan, R and Senger, JL and Ahmed, S and Kanthan, SC. [object Object]. J Oncol [online]. 2015, vol. 2015, p. 967472.

8. Agha, SA and Fowler, AJ and Saeta, A and Barai, I and Rajmohan, S and Orgill, DP. The SCARE statement: consensus-based surgical report guidelines. Int J Surg [online]. 2016, vol. 34, p. 180-186.

9. Oohashi, Y and Shirai, Y and Wakai, T and Nagakura, S and Watanabe, H and Hatakeyama, K. Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible. Cancer [online]. 2002, vol. 94, p. 3000-3005.

10. Kalayarasan, R and Javed, A and Sakhuja, P and Agarwal, AK. Squamous variant of gallbladder cancer: Is it different from adenocarcinoma?. Am J Surg [online]. 2013, vol. 206, p. 380-385.

11. Tella, SH and Kommalapati, A and Borad, MJ and Mahipal, A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol [online]. 2020, vol. 21, p. e29-e41.

12. Aldossary, MY and Alayed, AA and Amr, S and Algahtani, MS. Primary squamous cell carcinoma of the gallbladder: report of a rare neoplasm from the Eastern Province of Saudi Arabia. In J Surg Case Rep [online]. 2018, vol. 51, p. 186-189.

13. Weathrall, TJ and Fenton, M and Munene, G and Dickson, PV and Deneve, JL. Locally advanced, unresectable squamous cell carcinoma of the gallbladder. Case Rep Surg [online]. 2015, vol. 2015, p. 424650.

14. Song, HW and Chen, C and Shen, HX and Ma, L and Zhao, YL and Zhang, GJ. Squamous/adenosquamous carcinoma of the gallbladder: analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma. J Surg Oncol [online]. 2013, vol. 112, p. 677-680.

15. Zou, XP and Wang, JY and Jiang, YY and Chen, G and Mo, WJ and Feng, ZB. Clinicopathological features and survival of gallbladder squamous cell carcinoma: analysis of 121 cases. Int J Clin Exp Pathol [online]. 2018, vol. 11, p. 3208-3221.

16. Cho, JK and Lee, W and Jang, JY and Kim, HG and Kim, JM and Kwag, SJ. Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study. World J Surg Oncol [online]. 2019, vol. 17, p. 8-18.

17. Lee, SE and Kim, KS and Kim, WB and Kim, IG and Nah, YW and Ryu, DH. Practical guidelines for the surgical treatment of gallbladder cancer. J Korean Med Sci [online]. 2014, vol. 29, p. 1333-1340.

18. Eckel, F and Brunner, T and Jelic, S and Groupa, EGW. Billiary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [online]. 2011, vol. 22, p. vi40-4.

19. National Comprehensive Cancer Network (NCCN). [object Object]. NCCN, 2015.

20. Valle, J and Wasan, H and Palmer, DH and Cunningham, D and Anthoney, A and Maraveyas, A. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med [online]. 2010, vol. 362, p. 1273-1281.

21. Ma, N and Hui, C and Qin, B and Zhong, R and Wang, B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer [online]. 2015, vol. 15, p. 615-624.

Article images

See where this article was accessed

Dados de acesso insuficientes para visualização no mapa.